OstomyNCT06524401
Novel Post-Surgical Incision Management to Prevent Ostomy Complications
A study testing Limpet in people with Ostomy and Enterocutaneous Fistula, run by HealthPartners Institute at 1 site in United States.
Trial summary
The goal of this clinical trial is to evaluate the safety and effectiveness of the Limpet, as compared to standard of care ostomy pouches, in reducing complications for ostomy and fistula patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ostomy, Enterocutaneous Fistula
- What is being tested?
- Limpet
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 92 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Nov 2024to Mar 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant is greater than 18 years of age, inclusive
- Participant is undergoing ileostomy surgery or,
- has an enterocutaneous fistula with output over 500cc in 24 hours
- Participants stoma will have a maximum diameter of 1.5 inches based on measurements from the Investigator or Sponsor.
- Area around the stoma must have no injury through the dermis (i.e., intact skin)
- Participant is willing and able to comply with all protocol-specified requirements
- Participant is capable of reading and understanding English and will provide written informed consent to participate.
Who cannot join
- Unable/unwilling to attend the follow-up appointments
- Participant has a life expectancy < 30 days.
- Participant has a stature too small for use of the Limpet in the opinion of the Investigator or Sponsor.
- Participant has an enteroatmospheric fistula (enteric fistula to an open wound)
- Participant is scheduling/planning concurrent chemotherapy or other radiation treatment during the study follow-up period
- Participant has a history of sensitivity or allergy to hydrocolloids or other materials in the Limpet device.
Show all 10Show fewer
- Participant is pregnant or planning to become pregnant (verbal report).
- Participant is unable or unwilling to provide informed consent.
- Participant is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.
- Participant has any other disease or medical condition that, in the opinion of the Investigator or Sponsor, could endanger the participant, interfere with the evaluation of the study device's efficacy or safety, or compromise the participant's ability to comply with/complete the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Regions Hospital
Saint Paul, Minnesota, 55101
Allison Kehren, 651-254-5342, Allison.J.Kehren@HealthPartners.Com
About this study
The goal of this clinical trial is to evaluate the safety and effectiveness of the Limpet, as compared to standard of care ostomy pouches, in reducing complications for ostomy and fistula patients. Secondary objectives include evaluating dressing leak rates and causes of complications (e.g., edema, tissue oxygen saturation, and poor stoma eversion). The main questions it aims to answer are:
Primary Hypothesis 1: Peristomal Skin Complications will decrease
Read more
Primary Hypothesis 2: Dressing Leak Rates will decrease
Participants will:
- Receive either the Limpet device or standard of care adhesive ostomy pouch dressing
- Return every 7 days for study visits for 30 days to receive device replacement, wound imaging, blood tests, and quality of life surveys.
Read the detailed description
The Limpet is a single-use device intended for effluent management and promotion of healing of intact and injured skin surrounding enterocutaneous fistulae and ostomies.
Our study focuses on small bowel openings, encompassing two important cohorts: 1) ileostomy and 2) enterocutaneous fistulas (ECFs). Our study's success criterion is primarily based on the pooled results from both cohorts.
Primary Hypothesis 1: Peristomal Skin Complications (PSCs): We hypothesize that the Limpet will demonstrate a significant improvement in PSCs compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 35% in PSCs for the pooled cohorts, with a complication rate of 50% in the control group and 15% in the Limpet group.
Primary Hypothesis 2: Dressing Leak Rates: We hypothesize that the Limpet will demonstrate a significant improvement in dressing leak rates compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 15% in leak rates for the pooled cohorts, with a leak rate of 30% in the control group and 15% in the Limpet group.
These hypotheses are grounded in existing literature, supplemented by clinical experience. We intend to conduct subgroup analyses to assess the treatment effect across the two cohorts (ileostomy and ECF) and across other relevant subgroups such as gender, race, etc.
Secondary Hypothesis: Total Complications (PSCs and Stomal Complications): We hypothesize that the Limpet will exhibit a raw difference of 35% in total complications (comprising PSCs and stomal complications like mucocutaneous separation and stoma retraction) for the ileostomy cohort. Stoma complication rates vary widely in the literature, and we plan to conduct sub analyses to evaluate the Limpet's effect on stoma complications independent of PSCs.
This will be a 30 day, single-site, randomized controlled trial (RCT) for a non-significant risk device, Limpet.
The study will have a two-arm parallel group design:
- Limpet: Participants in this arm will utilize the subject device as intended to be used.
- Control: Standard treatment with standard of care adhesive ostomy pouches.
Ninety-two participants (78 stoma and 14 enterocutaneous fistula participants) will be randomized after they have consented to study participation. Initial randomization will occur in a 1:1 ratio (Limpet and Control). Participants will be randomly stratified with permuted blocks by BMI (≤ vs > 40) and stoma type (loop ileostomy, end ileostomy, or enterocutaneous fistula) to account differences in healing and wound severity.
This study will be conducted at HealthPartners Institute's Regions Hospital in St. Paul, Minnesota. Data compiled by the Wound, Ostomy, and Continence Nursing Department reveals an annual pool of more than 300 eligible patients at Regions Hospital.
The study will consist of the following visits:
- Visit C1 (Day -35 to -6): Screening in-person clinic visit
- Visit C2, Day 1: Baseline appointment clinic visit
- Visit C3, Week 1: Clinic visit
- Visit C4, Week 2: Clinic visit
- Visit C5, Week 3: Clinic visit
- Visit C6, Week 4: Final appointment during treatment period; clinic visit
After the Baseline Data Collection Period, participants will be randomized by BMI and three stoma types: ileostomy with loop stoma, ileostomy with end stoma, and enterocutaneous fistulas (ECFs) into 1 of 2 treatment groups:
- Limpet: Participants in this arm will utilize the subject device as intended to be used.
- Control: Standard treatment with standard of care adhesive ostomy pouches.
On Day 1, Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.
On Day 1, Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.
The brand and model of pumps and adhesive ostomy pouches used by Limpet and Control participants will be recorded for comparison purposes. Participants will return for clinic visits approximately every 7 days to have their device replaced. Participants will have their final study appointment approximately 30 days post-surgery. Clinical support will help the participant troubleshoot dressing problems; and if necessary, bring the patient into the study site for an immediate dressing change.
- Conditions
- Ostomy, Enterocutaneous Fistula
- Being tested
- Limpet, Control
- Keywords
- Stoma, Ileostomy
- Medical subject headings
- Intestinal Fistula
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LimpetDevice
Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.
ControlDevice
Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.
| Study group | Role | What they receive |
|---|---|---|
| Limpet | Experimental | Participants in this arm will utilize the subject device as intended to be used. Receives: Device: Limpet |
| Control | Active comparator | Standard treatment with standard of care adhesive ostomy pouches. Receives: Device: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peristomal Skin Complications (PSCs)
We hypothesize that the Limpet will demonstrate a significant improvement in PSCs compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 35% in PSCs for the pooled cohorts, with a complication rate of 50% in the control group and 15% in the Limpet group.
Measured: 30 days
Dressing Leak Rates
We hypothesize that the Limpet will demonstrate a significant improvement in dressing leak rates compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 15% in leak rates for the pooled cohorts, with a leak rate of 30% in the control group and 15% in the Limpet group.
Measured: 30 Days
Secondary outcomes (1)
Total Complications (PSCs and Stomal Complications)
We hypothesize that the Limpet will exhibit a raw difference of 35% in total complications (comprising PSCs and stomal complications like mucocutaneous separation and stoma retraction) for the ileostomy cohort. Stoma complication rates vary widely in the literature, and we plan to conduct sub analyses to evaluate the Limpet's effect on stoma complications independent of PSCs.
Measured: 30 Days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2024
- Study start18 Nov 2024
- Primary completionJan 2029 (estimated)
- Study completionMar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OstomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 92 participants (estimated)
Sponsor and investigators
- Lead sponsor
- HealthPartners Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06524401
- Sponsor's protocol ID
- A22-066
- Status last verified
- Oct 2026
- First submitted
- 23 Jul 2024
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will not be shared with external entities outside of aggregate form for publication. Deidentified data will be shared with the study sponsor. Study identifiers will be destroyed after publication.
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Novel Post-Surgical Incision Management to Prevent Ostomy Complications
- ClinicalTrials.gov ID
- NCT06524401
- Acronym / sponsor ID
- A22-066
- Conditions
- Ostomy, Enterocutaneous Fistula
- Keywords
- Stoma, Ileostomy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 92 participants (estimated)
- Lead sponsor
- HealthPartners InstituteUniversity, hospital or other
- Study start
- 18 Nov 2024 (actual)
- Primary completion
- Jan 2029 (estimated)
- Study completion
- Mar 2029 (estimated)
- First posted
- 29 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the safety and effectiveness of the Limpet, as compared to standard of care ostomy pouches, in reducing complications for ostomy and fistula patients. Secondary objectives include evaluating dressing leak rates and causes of complications (e.g., edema, tissue oxygen saturation, and poor stoma eversion). The main questions it aims to answer are:
Primary Hypothesis 1: Peristomal Skin Complications will decrease
Primary Hypothesis 2: Dressing Leak Rates will decrease
Participants will:
- Receive either the Limpet device or standard of care adhesive ostomy pouch dressing
- Return every 7 days for study visits for 30 days to receive device replacement, wound imaging, blood tests, and quality of life surveys.
Detailed description
The Limpet is a single-use device intended for effluent management and promotion of healing of intact and injured skin surrounding enterocutaneous fistulae and ostomies.
Our study focuses on small bowel openings, encompassing two important cohorts: 1) ileostomy and 2) enterocutaneous fistulas (ECFs). Our study's success criterion is primarily based on the pooled results from both cohorts.
Primary Hypothesis 1: Peristomal Skin Complications (PSCs): We hypothesize that the Limpet will demonstrate a significant improvement in PSCs compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 35% in PSCs for the pooled cohorts, with a complication rate of 50% in the control group and 15% in the Limpet group.
Primary Hypothesis 2: Dressing Leak Rates: We hypothesize that the Limpet will demonstrate a significant improvement in dressing leak rates compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 15% in leak rates for the pooled cohorts, with a leak rate of 30% in the control group and 15% in the Limpet group.
These hypotheses are grounded in existing literature, supplemented by clinical experience. We intend to conduct subgroup analyses to assess the treatment effect across the two cohorts (ileostomy and ECF) and across other relevant subgroups such as gender, race, etc.
Secondary Hypothesis: Total Complications (PSCs and Stomal Complications): We hypothesize that the Limpet will exhibit a raw difference of 35% in total complications (comprising PSCs and stomal complications like mucocutaneous separation and stoma retraction) for the ileostomy cohort. Stoma complication rates vary widely in the literature, and we plan to conduct sub analyses to evaluate the Limpet's effect on stoma complications independent of PSCs.
This will be a 30 day, single-site, randomized controlled trial (RCT) for a non-significant risk device, Limpet.
The study will have a two-arm parallel group design:
- Limpet: Participants in this arm will utilize the subject device as intended to be used.
- Control: Standard treatment with standard of care adhesive ostomy pouches.
Ninety-two participants (78 stoma and 14 enterocutaneous fistula participants) will be randomized after they have consented to study participation. Initial randomization will occur in a 1:1 ratio (Limpet and Control). Participants will be randomly stratified with permuted blocks by BMI (≤ vs > 40) and stoma type (loop ileostomy, end ileostomy, or enterocutaneous fistula) to account differences in healing and wound severity.
This study will be conducted at HealthPartners Institute's Regions Hospital in St. Paul, Minnesota. Data compiled by the Wound, Ostomy, and Continence Nursing Department reveals an annual pool of more than 300 eligible patients at Regions Hospital.
The study will consist of the following visits:
- Visit C1 (Day -35 to -6): Screening in-person clinic visit
- Visit C2, Day 1: Baseline appointment clinic visit
- Visit C3, Week 1: Clinic visit
- Visit C4, Week 2: Clinic visit
- Visit C5, Week 3: Clinic visit
- Visit C6, Week 4: Final appointment during treatment period; clinic visit
After the Baseline Data Collection Period, participants will be randomized by BMI and three stoma types: ileostomy with loop stoma, ileostomy with end stoma, and enterocutaneous fistulas (ECFs) into 1 of 2 treatment groups:
- Limpet: Participants in this arm will utilize the subject device as intended to be used.
- Control: Standard treatment with standard of care adhesive ostomy pouches.
On Day 1, Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.
On Day 1, Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.
The brand and model of pumps and adhesive ostomy pouches used by Limpet and Control participants will be recorded for comparison purposes. Participants will return for clinic visits approximately every 7 days to have their device replaced. Participants will have their final study appointment approximately 30 days post-surgery. Clinical support will help the participant troubleshoot dressing problems; and if necessary, bring the patient into the study site for an immediate dressing change.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Limpet | Experimental | Device: LimpetParticipants in this arm will utilize the subject device as intended to be used. |
| Control | Active comparator | Device: ControlStandard treatment with standard of care adhesive ostomy pouches. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Participant is greater than 18 years of age, inclusive
- Participant is undergoing ileostomy surgery or,
- has an enterocutaneous fistula with output over 500cc in 24 hours
- Participants stoma will have a maximum diameter of 1.5 inches based on measurements from the Investigator or Sponsor.
- Area around the stoma must have no injury through the dermis (i.e., intact skin)
Key exclusion criteria (10 listed)
- Unable/unwilling to attend the follow-up appointments
- Participant has a life expectancy < 30 days.
- Participant has a stature too small for use of the Limpet in the opinion of the Investigator or Sponsor.
- Participant has an enteroatmospheric fistula (enteric fistula to an open wound)
- Participant is scheduling/planning concurrent chemotherapy or other radiation treatment during the study follow-up period
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LimpetLimpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure. | Device | Limpet |
| ControlControl participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care. | Device | Control |
Primary outcome
Peristomal Skin Complications (PSCs)
Time frame: 30 days
We hypothesize that the Limpet will demonstrate a significant improvement in PSCs compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 35% in PSCs for the pooled cohorts, with a complication rate of 50% in the control group and 15% in the Limpet group.
Dressing Leak Rates
Time frame: 30 Days
We hypothesize that the Limpet will demonstrate a significant improvement in dressing leak rates compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 15% in leak rates for the pooled cohorts, with a leak rate of 30% in the control group and 15% in the Limpet group.
1 secondary outcome
Total Complications (PSCs and Stomal Complications)
Time frame: 30 Days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No. Data will not be shared with external entities outside of aggregate form for publication. Deidentified data will be shared with the study sponsor. Study identifiers will be destroyed after publication.
Related trials for Ostomy
Recruiting
Conducting Wound, Ostomy, and Continence (WOC) Nurse Telephone Follow-up for Post-discharge Ostomy Patients to Reduce Hospital Readmission
Ostomy
Not yet recruiting
Suture Choice for Ostomy Creation
Ostomy - Ileostomy or Colostomy, Stoma Complications
Active, not recruiting
The Effect of Planned Group Interaction on Ostomy Adaptation, Quality of Life, and Stoma Care Self-Efficacy Levels in Individuals With an Ostomy
Ostomy - Ileostomy or Colostomy
Active, not recruiting
ColoSeal™ ICD System Anastomotic Protection Pivotal Study
Rectal Cancer Surgery
Recruiting
ColoSeal™ ICD System Safety and Feasibility Studies
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Limpet in people with Ostomy and Enterocutaneous Fistula, run by HealthPartners Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Allison Kehren (651-254-5342, Allison.J.Kehren@HealthPartners.Com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peristomal Skin Complications (PSCs) (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.